219 related articles for article (PubMed ID: 2378882)
21. Characterization of organ-specific immunoliposomes for delivery of 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in a mouse lung-metastasis model.
Mori A; Kennel SJ; van Borssum Waalkes M; Scherphof GL; Huang L
Cancer Chemother Pharmacol; 1995; 35(6):447-56. PubMed ID: 7882453
[TBL] [Abstract][Full Text] [Related]
22. Lipid composition is important for highly efficient target binding and retention of immunoliposomes.
Maruyama K; Kennel SJ; Huang L
Proc Natl Acad Sci U S A; 1990 Aug; 87(15):5744-8. PubMed ID: 2377612
[TBL] [Abstract][Full Text] [Related]
23. Coupling of metal containing homing devices to liposomes via a maleimide linker: use of TCEP to stabilize thiol-groups without scavenging metals.
Visser CC; Voorwinden LH; Harders LR; Eloualid M; van Bloois L; Crommelin DJ; Danhof M; de Boer AG
J Drug Target; 2004; 12(9-10):569-73. PubMed ID: 15621682
[TBL] [Abstract][Full Text] [Related]
24. The use of monoclonal anti-Thy1 IgG1 for the targeting of liposomes to AKR-A cells in vitro and in vivo.
Wolff B; Gregoriadis G
Biochim Biophys Acta; 1984 Nov; 802(2):259-73. PubMed ID: 6498219
[TBL] [Abstract][Full Text] [Related]
25. Target-sensitive immunoliposomes as an efficient drug carrier for antiviral activity.
Ho RJ; Rouse BT; Huang L
J Biol Chem; 1987 Oct; 262(29):13973-8. PubMed ID: 2820987
[TBL] [Abstract][Full Text] [Related]
26. Brain drug delivery of small molecules using immunoliposomes.
Huwyler J; Wu D; Pardridge WM
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14164-9. PubMed ID: 8943078
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody covalently coupled to liposomes: specific targeting to cells.
Barbet J; Machy P; Leserman LD
J Supramol Struct Cell Biochem; 1981; 16(3):243-58. PubMed ID: 7031274
[TBL] [Abstract][Full Text] [Related]
28. The development of IL-2 conjugated liposomes for therapeutic purposes.
Konigsberg PJ; Godtel R; Kissel T; Richer LL
Biochim Biophys Acta; 1998 Mar; 1370(2):243-51. PubMed ID: 9545572
[TBL] [Abstract][Full Text] [Related]
29. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
30. Preparation of Immunoliposomes by Direct Coupling of Antibodies Based on a Thioether Bond.
Petrilli R; Eloy JO; Lee RJ; Lopez RFV
Methods Mol Biol; 2018; 1674():229-237. PubMed ID: 28921442
[TBL] [Abstract][Full Text] [Related]
31. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat.
Huwyler J; Yang J; Pardridge WM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1541-6. PubMed ID: 9316870
[TBL] [Abstract][Full Text] [Related]
32. Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin.
Lundberg BB; Griffiths G; Hansen HJ
Int J Pharm; 2000 Sep; 205(1-2):101-8. PubMed ID: 11000546
[TBL] [Abstract][Full Text] [Related]
33. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target.
Klibanov AL; Maruyama K; Beckerleg AM; Torchilin VP; Huang L
Biochim Biophys Acta; 1991 Feb; 1062(2):142-8. PubMed ID: 2004104
[TBL] [Abstract][Full Text] [Related]
34. Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity.
Kamps JA; Swart PJ; Morselt HW; Pauwels R; De Béthune MP; De Clercq E; Meijer DK; Scherphof GL
Biochim Biophys Acta; 1996 Jan; 1278(2):183-90. PubMed ID: 8593275
[TBL] [Abstract][Full Text] [Related]
35. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC
Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130
[TBL] [Abstract][Full Text] [Related]
36. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide.
Pagnan G; Montaldo PG; Pastorino F; Raffaghello L; Kirchmeier M; Allen TM; Ponzoni M
Int J Cancer; 1999 Apr; 81(2):268-74. PubMed ID: 10188730
[TBL] [Abstract][Full Text] [Related]
37. [Study on preparation and biodistribution of PEG-immunoliposomes with active carboxylic terminals].
Zhang YF; Xie SS; Hou XP; Gao X; Zhang S; Chen ZS
Yao Xue Xue Bao; 2000 Nov; 35(11):854-9. PubMed ID: 11218866
[TBL] [Abstract][Full Text] [Related]
38. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin.
Tardi PG; Swartz EN; Harasym TO; Cullis PR; Bally MB
J Immunol Methods; 1997 Dec; 210(2):137-48. PubMed ID: 9520297
[TBL] [Abstract][Full Text] [Related]
39. Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.
Koning GA; Kamps JA; Scherphof GL
Cancer Detect Prev; 2002; 26(4):299-307. PubMed ID: 12430634
[TBL] [Abstract][Full Text] [Related]
40. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
